V-Body platform

Valerio Therapeutics is leveraging a new generation of ultra-small antibody therapeutics (15 kDa) capable of accessing previously unreachable targets. These single-domain antibodies (sdAbs) offer:

• Enhanced tissue penetration – Their reduced size enables superior access to diseased tissues.
• High specificity & affinity – Designed to bind even the most hidden epitopes.
• Scalability & flexibility – Fully synthetic, easy to manufacture, and adaptable for multivalency and multispecificity.

This innovative platform represents a paradigm shift in targeted therapy, bringing us closer to precision-guided, highly effective treatments.

Our v-body proprietary discovery platform enables the rapid identification and optimization of single-domain antibodies with:

• High affinity & specificity – Designed to selectively bind disease-driving targets.
• Efficient screening capabilities – Accelerating the development process.
• Enhanced functionality – Tailored for deep tissue penetration and intracellular delivery.

This fully integrated selection process allows us to generate highly effective and next-generation therapeutic candidates with superior performance in less than 2 months.

A unique discovery path: disease <-> target tackling target identification limitations

Traditional drug discovery often faces challenges in identifying and validating optimal therapeutic targets. Leveraging V-Body proprietary discovery platform offers a next-generation target discovery path that:

• Focuses on disease-specific mechanisms – Ensuring that targets are clinically relevant.
• Uses advanced computational and experimental models – Enhancing predictive accuracy.
• Accelerates development timelines – Shortening the path from discovery to clinical application.

By overcoming target identification barriers, we unlock new possibilities for precision medicine.